Fulcrum continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia, and plans to ...

Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a ...

Analysts estimate that Fulcrum Therapeutics will report an earnings per share (EPS) of $-0.26. Fulcrum Therapeutics bulls ...

Fulcrum IT Partners says that it is on course for 2023 revenues of $1 billion following its acquisition of London-based Viadex. Viadex CEO CEO Dino Cooper. Viadex’s takeover by ambitious buy-and ...

the potential of pociredir to increase HbF to levels that could ameliorate symptoms of SCD and transform the standard of care; Fulcrum’s ability to progress its early stage development programs ...